Dr. Michelle Henry Highlights Noninvasive Periorbital Rejuvenation

Understanding facial aging patterns specific to richly pigmented skin and adjusting treatment approaches accordingly, especially as patient preferences shift away from traditional lower eyelid filler, is key in managing periorbital aging in patients with skin of color, Michelle Henry, MD, FAAD, said at the Skin of Color Update in New York, New York.

Periorbital aging manifests early in patients of African descent due to common anatomic features, such as malar prominence and earlier herniation of orbital fat, Dr. Henry said. She added that this anatomical tendency has historically driven robust use of filler in the tear trough and infraorbital region to camouflage fat pads and contour the under-eye.

However, many patients are now opting out of under-eye filler due to concerns about safety, aesthetics, and overtreatment.

“We can still achieve good results with filler,” Dr. Henry said, “but we may have overused it for a period of time, and patients are pushing back.”

In response to this shift, a novel application of a high-intensity facial electrical stimulation device has emerged as a promising alternative for periorbital rejuvenation. Originally designed for facial toning, this device now features an eye-specific applicator that targets the orbicularis oculi and lower eyelid musculature.

“Aging is not just about collagen loss—it’s dynamic,” Dr. Henry said. “Muscles weaken over time, reducing resistance against orbital fat and lymphatic drainage. That’s where this new modality offers real value.”

The targeted stimulation acts as a “workout” for the periorbital musculature, strengthening the tissue and promoting visible tightening. According to Dr. Henry, the treatment not only reduces puffiness and under-eye bags but also softens fine lines and crow’s feet, all without the trauma or downtime associated with filler or surgery.

“For patients who are hesitant about surgery or filler, especially those looking for minimal downtime, this is an exciting, effective option,” Dr. Henry said.

As preferences evolve, especially among patients with skin of color who may be at higher risk of pigmentary complications or swelling with injectables, having a muscle-based, device-driven alternative offers both clinical utility and patient appeal. For dermatologists who do not perform blepharoplasty, Dr. Henry said, this technology provides a new tool in the armamentarium for addressing lower eyelid aging.